What it means
The sector splits broadly into two halves that behave quite differently. On one side sit providers, distributors and equipment makers, whose revenue is tied to procedure volumes and reimbursement rates.
On the other sit pharmaceuticals and biotechnology, where value depends on patents, pipelines and trial outcomes. Sector labels drive how portfolios are built, how analysts are assigned and how a company is benchmarked.
A business classified as healthcare will be compared against healthcare peers on margin, growth and multiple, whether or not that comparison flatters it. Investors calculate a sector weight, meaning the sector's share of total index value, then compare their own holdings against it to see whether they are overweight or underweight.
Multiplying that weight by the sector's return gives the sector's contribution to the overall portfolio return. Healthcare is defensive in demand but not in policy.
Reimbursement rules, drug pricing decisions and regulatory approvals can reprice large parts of the sector within days, and biotechnology in particular behaves far more like a high-growth sector, with binary outcomes tied to individual trial results. Demographics are the long-run argument for the sector.
Populations in most developed economies are ageing, and older patients consume several times more medical care than younger ones, which supports volume growth almost regardless of the economic cycle. The catch is that the same demographics strain the public and insurance budgets that ultimately pay the bills, which is where the pricing pressure comes from.
In practice
Real-world examples.
Example
A pension fund reviews its equity book and finds healthcare at 17% against a 12% benchmark weight. The investment committee decides to trim back to 14%, keeping a modest tilt while cutting the position that had drifted through strong performance.
Example
A private medical device manufacturer preparing for sale benchmarks its 48% gross margin against a sector median nearer 55%. The gap becomes the central question in every buyer meeting and shapes a two-year pricing programme before the sale process starts.
Example
A hospital staffing agency uses the sector's defensive reputation to argue for a lower borrowing rate at refinancing. The lender accepts that demand is stable but prices in reimbursement risk, landing at a rate between the agency's ask and its previous terms. The finance director keeps the sector comparison in the annual lender pack, because it reframes the conversation from company history to industry behaviour.
Formula
Calculation
Sector weight = sector market capitalisation / total index market capitalisation. Contribution to return = sector weight x sector return.
An index has a total market capitalisation of $48,000,000,000,000, and the healthcare companies within it are worth $5,760,000,000,000 in total. The sector weight is $5,760,000,000,000 / $48,000,000,000,000 = 0.12, or 12%.
If healthcare returns 8% over the year, its contribution to the index return is 0.12 x 8% = 0.96%. A fund holding 17% in healthcare is overweight by 17% - 12% = 5 percentage points, and that extra 5% earning the same 8% adds 0.05 x 8% = 0.40% of relative return before fees and trading costs.Case study
Seen in the real world.
Meridian Wealth Partners is an illustrative fictional advisory firm managing a $500,000 model portfolio for a retired client who wanted income and stability. Over three strong years the healthcare allocation had drifted to 22%, or 0.22 x $500,000 = $110,000, against a benchmark weight of 12%, or 0.12 x $500,000 = $60,000. The overweight position was therefore $110,000 - $60,000 = $50,000.
A change to reimbursement rules then knocked 9% off the sector in a month. The overweight portion alone cost the client $50,000 x 0.09 = $4,500 of relative performance, on top of the loss the benchmark weight would have produced anyway.
The adviser's review made two changes. Drift limits were set so any sector more than 4 percentage points from benchmark triggers a rebalancing conversation, and the healthcare holding was split between providers and pharmaceuticals rather than treated as one exposure, on the grounds that the two halves rarely move together.
Watch out
Common mistakes.
- Treating the whole sector as one defensive block, when biotechnology behaves far more like a speculative growth investment.
- Assuming demand stability means earnings stability, while ignoring that governments and insurers set much of the pricing.
- Letting a strong-performing sector drift well above its target weight and calling the result a deliberate strategy.
Questions
People also ask.
Why is healthcare called defensive?
Because demand for treatment holds up through recessions, so revenue tends to fall less than in discretionary sectors such as travel or luxury goods.
What is the biggest risk to the sector?
Policy and reimbursement change, since a single decision on pricing or coverage can move revenue for many companies at once.
Does holding a healthcare fund give diversification?
Only within the sector, so it concentrates rather than spreads risk unless it sits alongside meaningful exposure elsewhere.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%